

ALIAS + protocolnummer	Target	EudraCT nummer	Protocoltitel
COBIRAF - ML29741	Dermatologie - melanoma	2015-001731-20	A SINGLE ARM, OPEN LABEL, PHASE II, MULTICENTER STUDY TO ASSESS THE DETECTION OF THE BRAF V600 MUTATION ON cfDNA FROM PLASMA IN PATIENTS WITH ADVANCED MELANOMA
TCRU CareMore	Borst		Voorspellende waarde van tumorcellen in het bloed in patiënten met uitgezaaide borstkanker behandeld met hormonale therapie (CareMore-AI studie)
TCRU Cisplatine MBC	Borst		Prospective evaluation of the predictive value of a circulating tumor cell (CTC) sensitivity profile to Ciplatin chemotherapy in metastatic breast cancer patients
TCRU CORE_ARV_CTC_CRPC	Urologie		Detection of aberrant androgen receptor transcripts in circulating tumour cells as a predictor of resistance to AR directed treatment in patients with castration resistant prostate cancer
CHECKMATE - CA209401	Dermatologie - melanoma	2015-001274-17	Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma
C31001	Borst	2014-001921-34	A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2 <sup>-</sup> Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant

ALIAS + protocolnummer	Target	EudraCT nummer	Protocoltitel
AURORA - BIG14-01	Borst		Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer The AURORA PROGRAM
PALLAS - AFT-05/ABCSG 42/BIG 14-03	Borst	2014-005181-30	PALLAS: PALbociclib CoLLaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
C31004	Gynaecologie - endometrium	2014-005394-37	A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3K $\alpha$ Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer
GALAHAD - 64091742PCR2001	Urologie	2016-002057-38	A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
POMP - KW1222RTH001021069	Urologie		Non-systemic treatment for patients with low-volume metastatic prostate cancer: a randomized phase II trial.
METRIC - CDX011-04	Borst	2015-003693-33	A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The "METRIC" Study)

<b>ALIAS + protocolnummer</b>	<b>Target</b>	<b>EudraCT nummer</b>	<b>Protocoltitel</b>
JAVELIN Bladder 100 - B9991001	Urologie	2015-003262-86	A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE AS A MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHOSE DISEASE DID NOT PROGRESS AFTER COMPLETION OF FIRST-LINE PLATINUM-CONTAINING CHEMOTHERAPY
Masterkey232 - 20130232	MKA - ORL	2015-003011-38	A Phase 1b/3 Multicenter, Randomized Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
CTMT212X2102	Studies verschillende indicaties	2015-004621-14	A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone plus Ethinyl Estradiol) in Female Patients with Solid Tumors
FORWARD1 - 0403	Gynaecologie - algemeen		FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women with Folate Receptor $\alpha$ -positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

<b>ALIAS + protocolnummer</b>	<b>Target</b>	<b>EudraCT nummer</b>	<b>Protocoltitel</b>
SOPHIA - CP-MGAH22-04	Borst	2015-000380-13	A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment
ATLAS - 56021927PCR3003	Urologie	2015-003007-38	A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
TRILOGY - CO39262	Dermatologie - melanoma	2016-002482-54	A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION-POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA
COMPLEMENT-1 - CLEE011A2404	Borst	2016-003467-19	COMPLEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease

ALIAS + protocolnummer	Target	EudraCT nummer	Protocoltitel
PYTHIA - IBCSG 53-14 BIG 14-04	Borst	2014-005387-15	A Phase II Study of Palbociclib plus Fulvestrant for pretreated patients with ER+/HER2- Metastatic Breast Cancer Palbociclib in molecularly characterized ER-positive/HER2-negative metastatic breast cancer: the PYTHIA study
adj RT blaasca UZ Gent	Urologie		Adjuvant radiotherapy after cystectomy for patients with muscle invasive bladder cancer: a phase II trial.
GO29674	Studies verschillende indicaties	2015-000516-18	A PHASE Ib, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MOXR0916 AND ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS
AMG820 - 20150195	Studies verschillende indicaties		A Phase 1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors
ARASENS - BAY1841788-17777	Urologie	2015-002590-38	A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
AIPAC - IMP321-P011	Borst	2015-002541-63	AIPAC (Active Immunotherapy PAclitaxel): A multicentre, Phase IIb, randomised, double blind, placebo-controlled study in hormone receptor-positive metastatic breast carcinoma patients receiving IMP321 (LAG-3Ig fusion protein) or placebo as adjunctive to a standard chemotherapy treatment regimen of paclitaxel.